Table 3.
Patient characteristics in MDZ group and DEX group before propensity score matching.
| MDZ group | DEX group | |
|---|---|---|
| N | 112 | 81 |
| Age (years) | 53.4 ± 18.7 | 52.9 ± 16.6 |
| Sex | ||
| Male | 74 | 53 |
| Female | 38 | 28 |
| Height (cm) | 163.6 ± 9.9 | 165.1 ± 9.3 |
| Weight (kg) | 56.2 ± 12.1 | 57.2 ± 12.0 |
| BMI | 20.9 ± 3.6 | 20.9 ± 3.4 |
| ASA-PS | ||
| ≥3 | 10 (8.9%) | 12 (14.8%) |
| ≤2 | 102 (91.1%) | 69 (85.2%) |
| Heart diseases | 10 (8.9%) | 7 (8.6%) |
| NYHA ≥3 | 0 | 2 (2.5%) |
| Respiratory diseases | 4 (3.6%) | 12 (14.8%) |
| Hugh–Jones ≥4 | 0 | 1 (1.2%) |
| History of surgery | 62 (55.3%) | 41 (50.6%) |
| Chronic renal failure | 6 (5.4%) | 4 (4.9%) |
| Chronic liver failure | 1 (0.9%) | 2 (2.5%) |
| Sleeping pills | 13 (11.6%) | 14 (17.3%) |
| Drinking history | Unknown | 29 (35.8%) |
| Smoking history | Unknown | 26 (32.1%) |
| Reasons of examinations | ||
| Crohn’s disease | 52 (46.4%) | 31 (38.3%) |
| Other IBD or suspected | 16 (14.3%) | 23 (28.4%) |
| Tumor or suspected | 21(18.8%) | 20(17.9%) |
| OGIB without tumor and IBD | 20 (17.8%) | 6 (7.4%) |
| Others | 3 (2.3%) | 1 (1.2%) |
MDZ: midazolam; DEX: dexmedetomidine; BMI: body mass index; ASA-PS: American Society of Anesthesiologists–physical status; NYHA: New York Heart Association; IBD: inflammatory bowel disease; OGIB: obscure gastrointestinal bleeding.